An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination With Chemotherapy, in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

This study is testing a new experimental drug called ORIC-114 to see how well it works to fight advanced solid tumors, either on its own or with chemotherapy. Researchers want to find the safest and most effective dose to help shrink tumors in patients whose cancers have specific gene changes.

This trial is for adults with advanced solid tumors (like lung or breast cancer) that have tested positive for specific genetic markers, such as EGFR or HER2 mutations. You may not be eligible if you have certain heart conditions, history of lung inflammation, or cancer that has spread to the fluid around your brain.

Participants will receive the new medication, either alone or combined with standard chemotherapy, while doctors closely monitor their health. You will have regular check-ups, blood tests, and scans to see how your body responds to the treatment and to ensure your safety.

The study is currently recruiting patients at medical centers in California, specifically in Duarte, Huntington Beach, and Irvine. If you are interested, your doctor can help you contact these locations to see if you qualify.